A Subgroup Reanalysis of the Efficacy of Bufei Huoxue Capsules in Patients With “Long‐Covid‐19”
ABSTRACT Bufei huoxue capsules (BFHX), manufactured products of traditional Chinese medicine, have demonstrated anti‐inflammatory properties and efficacy against chronic pulmonary diseases and COVID‐19. This study was designed to further determine the clinical efficacy of BFHX in diverse patient sub...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | Pulmonary Circulation |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/pul2.70084 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849418879865978880 |
|---|---|
| author | Chi Hou Yue Xing Yuqin Chen Tingping Wang Jingjing Qi Xiaoqing Jia Xiansheng Zeng Jianling Bai Wenju Lu Yu Deng Bihua Zhong Yongxia Lei Yilin Chen Zhan Lian Haohao Zhou Junping Yan Xuejiao Yang Hao Yu Jiawei Zhou Lixia Qiu Yunliang Zhai Wanli Geng Nanshan Zhong Chunli Liu Jian Wang |
| author_facet | Chi Hou Yue Xing Yuqin Chen Tingping Wang Jingjing Qi Xiaoqing Jia Xiansheng Zeng Jianling Bai Wenju Lu Yu Deng Bihua Zhong Yongxia Lei Yilin Chen Zhan Lian Haohao Zhou Junping Yan Xuejiao Yang Hao Yu Jiawei Zhou Lixia Qiu Yunliang Zhai Wanli Geng Nanshan Zhong Chunli Liu Jian Wang |
| author_sort | Chi Hou |
| collection | DOAJ |
| description | ABSTRACT Bufei huoxue capsules (BFHX), manufactured products of traditional Chinese medicine, have demonstrated anti‐inflammatory properties and efficacy against chronic pulmonary diseases and COVID‐19. This study was designed to further determine the clinical efficacy of BFHX in diverse patient subgroups during the convalescent phase of COVID‐19, extending upon previously reported findings from a multicenter randomized controlled trial. Patients who had clinically recovered from COVID‐19 were blindly assigned to BFHX or placebo groups. All enrolled patients underwent chest computed tomography (CT) imaging, 6‐min walking distance (6MWD) test, and fatigue assessment inventory (FAI) at monthly follow‐up for 3 months. A post hoc subgroup reanalysis was performed on subgroups of sex, age, severity of acute illness, and positive/negative IgG antibody against S antigen variants. A total of 129 patients were enrolled in BFHX (N = 64) and placebo groups (N = 65). The 6MWD and FAI scores were more significantly improved in females and mild patients than in males and severe patients after BFHX treatment. Lung CT image evaluated by the change in whole lung volume and mean CT value showed that the patients below 60 years gained more therapeutic effects after 3 months of BFHX treatment (p = 0.0008; p = 0.017; p = 0.0313, respectively). The subgroup reanalysis implies that the therapeutic effectiveness of BFHX in managing COVID‐19 convalescence could potentially be influenced by factors including gender, age, and disease severity. Trial registration: This study was registered with the China Clinical Trial Registration Center (registration number: ChiCTR2000032573). |
| format | Article |
| id | doaj-art-0bf8ebd63d4b4f83af01a0f422f2e545 |
| institution | Kabale University |
| issn | 2045-8940 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pulmonary Circulation |
| spelling | doaj-art-0bf8ebd63d4b4f83af01a0f422f2e5452025-08-20T03:32:18ZengWileyPulmonary Circulation2045-89402025-04-01152n/an/a10.1002/pul2.70084A Subgroup Reanalysis of the Efficacy of Bufei Huoxue Capsules in Patients With “Long‐Covid‐19”Chi Hou0Yue Xing1Yuqin Chen2Tingping Wang3Jingjing Qi4Xiaoqing Jia5Xiansheng Zeng6Jianling Bai7Wenju Lu8Yu Deng9Bihua Zhong10Yongxia Lei11Yilin Chen12Zhan Lian13Haohao Zhou14Junping Yan15Xuejiao Yang16Hao Yu17Jiawei Zhou18Lixia Qiu19Yunliang Zhai20Wanli Geng21Nanshan Zhong22Chunli Liu23Jian Wang24State Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou ChinaState Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou ChinaState Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou ChinaDepartment of Out‐Patient and Emergency Wuhan Institute for Tuberculosis Control, Wuhan Pulmonary Hospital Wuhan ChinaDepartment of Respiratory and Critical Care Medicine Xiangzhou District People's Hospital Xiangyang ChinaDepartment of Respiratory Third Hospital of Baotou City Baotou ChinaDepartment of Respiratory and Critical Care Medicine Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science Xiangyang Hubei ChinaDepartment of Biostatistics, School of Public Health Nanjing Medical University Nanjing ChinaState Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou ChinaDepartment of Radiology The First Affiliated Hospital of Guangzhou Medical University Guangzhou ChinaState Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou ChinaDepartment of Radiology The First Affiliated Hospital of Guangzhou Medical University Guangzhou ChinaState Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou ChinaDepartment of Out‐Patient and Emergency Wuhan Institute for Tuberculosis Control, Wuhan Pulmonary Hospital Wuhan ChinaDepartment of Respiratory and Critical Care Medicine Xiangzhou District People's Hospital Xiangyang ChinaDepartment of Respiratory Third Hospital of Baotou City Baotou ChinaDepartment of Respiratory and Critical Care Medicine Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science Xiangyang Hubei ChinaDepartment of Biostatistics, School of Public Health Nanjing Medical University Nanjing ChinaDepartment of Biostatistics, School of Public Health Nanjing Medical University Nanjing ChinaHangzhou YITU Healthcare Technology Co. Ltd. Hangzhou ChinaDepartment of R&D Guangdong Leiyunshang Pharmaceutical Co. Ltd. Yunfu ChinaDepartment of R&D Guangdong Leiyunshang Pharmaceutical Co. Ltd. Yunfu ChinaState Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou ChinaState Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou ChinaState Key Laboratory of Respiratory Disease, National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health The First Affiliated Hospital of Guangzhou Medical University Guangzhou ChinaABSTRACT Bufei huoxue capsules (BFHX), manufactured products of traditional Chinese medicine, have demonstrated anti‐inflammatory properties and efficacy against chronic pulmonary diseases and COVID‐19. This study was designed to further determine the clinical efficacy of BFHX in diverse patient subgroups during the convalescent phase of COVID‐19, extending upon previously reported findings from a multicenter randomized controlled trial. Patients who had clinically recovered from COVID‐19 were blindly assigned to BFHX or placebo groups. All enrolled patients underwent chest computed tomography (CT) imaging, 6‐min walking distance (6MWD) test, and fatigue assessment inventory (FAI) at monthly follow‐up for 3 months. A post hoc subgroup reanalysis was performed on subgroups of sex, age, severity of acute illness, and positive/negative IgG antibody against S antigen variants. A total of 129 patients were enrolled in BFHX (N = 64) and placebo groups (N = 65). The 6MWD and FAI scores were more significantly improved in females and mild patients than in males and severe patients after BFHX treatment. Lung CT image evaluated by the change in whole lung volume and mean CT value showed that the patients below 60 years gained more therapeutic effects after 3 months of BFHX treatment (p = 0.0008; p = 0.017; p = 0.0313, respectively). The subgroup reanalysis implies that the therapeutic effectiveness of BFHX in managing COVID‐19 convalescence could potentially be influenced by factors including gender, age, and disease severity. Trial registration: This study was registered with the China Clinical Trial Registration Center (registration number: ChiCTR2000032573).https://doi.org/10.1002/pul2.70084bufei huoxue capsulespost‐acute COVID‐19 syndromesubgroup reanalysissymptom recoverytraditional Chinese medicine |
| spellingShingle | Chi Hou Yue Xing Yuqin Chen Tingping Wang Jingjing Qi Xiaoqing Jia Xiansheng Zeng Jianling Bai Wenju Lu Yu Deng Bihua Zhong Yongxia Lei Yilin Chen Zhan Lian Haohao Zhou Junping Yan Xuejiao Yang Hao Yu Jiawei Zhou Lixia Qiu Yunliang Zhai Wanli Geng Nanshan Zhong Chunli Liu Jian Wang A Subgroup Reanalysis of the Efficacy of Bufei Huoxue Capsules in Patients With “Long‐Covid‐19” Pulmonary Circulation bufei huoxue capsules post‐acute COVID‐19 syndrome subgroup reanalysis symptom recovery traditional Chinese medicine |
| title | A Subgroup Reanalysis of the Efficacy of Bufei Huoxue Capsules in Patients With “Long‐Covid‐19” |
| title_full | A Subgroup Reanalysis of the Efficacy of Bufei Huoxue Capsules in Patients With “Long‐Covid‐19” |
| title_fullStr | A Subgroup Reanalysis of the Efficacy of Bufei Huoxue Capsules in Patients With “Long‐Covid‐19” |
| title_full_unstemmed | A Subgroup Reanalysis of the Efficacy of Bufei Huoxue Capsules in Patients With “Long‐Covid‐19” |
| title_short | A Subgroup Reanalysis of the Efficacy of Bufei Huoxue Capsules in Patients With “Long‐Covid‐19” |
| title_sort | subgroup reanalysis of the efficacy of bufei huoxue capsules in patients with long covid 19 |
| topic | bufei huoxue capsules post‐acute COVID‐19 syndrome subgroup reanalysis symptom recovery traditional Chinese medicine |
| url | https://doi.org/10.1002/pul2.70084 |
| work_keys_str_mv | AT chihou asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT yuexing asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT yuqinchen asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT tingpingwang asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT jingjingqi asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT xiaoqingjia asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT xianshengzeng asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT jianlingbai asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT wenjulu asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT yudeng asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT bihuazhong asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT yongxialei asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT yilinchen asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT zhanlian asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT haohaozhou asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT junpingyan asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT xuejiaoyang asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT haoyu asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT jiaweizhou asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT lixiaqiu asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT yunliangzhai asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT wanligeng asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT nanshanzhong asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT chunliliu asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT jianwang asubgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT chihou subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT yuexing subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT yuqinchen subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT tingpingwang subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT jingjingqi subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT xiaoqingjia subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT xianshengzeng subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT jianlingbai subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT wenjulu subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT yudeng subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT bihuazhong subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT yongxialei subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT yilinchen subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT zhanlian subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT haohaozhou subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT junpingyan subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT xuejiaoyang subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT haoyu subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT jiaweizhou subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT lixiaqiu subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT yunliangzhai subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT wanligeng subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT nanshanzhong subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT chunliliu subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 AT jianwang subgroupreanalysisoftheefficacyofbufeihuoxuecapsulesinpatientswithlongcovid19 |